Phase IV, Non-interventional, Prospective, Open Label, Non Comparative Real Life Data Collection of Depo-Eligard 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients
Phase of Trial: Phase IV
Latest Information Update: 10 Jun 2014
At a glance
- Drugs Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Acronyms TREMODI
- Sponsors Astellas Pharma
- 10 Jun 2017 Biomarkers information updated
- 10 Jan 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 21 Nov 2013 Planned End Date changed from 1 Oct 2015 to 1 Dec 2013 as reported by ClinicalTrials.gov.